STOCK TITAN

Aligos Therapeutics Inc - ALGS STOCK NEWS

Welcome to our dedicated news page for Aligos Therapeutics (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aligos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aligos Therapeutics's position in the market.

Rhea-AI Summary
Aligos Therapeutics, Inc. (ALGS) will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024. The company focuses on developing therapeutics for liver and viral diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
conferences
-
Rhea-AI Summary
Aligos Therapeutics, Inc. initiates dosing in Phase 2a HERALD study of ALG-055009 for metabolic dysfunction-associated steatohepatitis (MASH), targeting liver and viral diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
-
Rhea-AI Summary
Aligos Therapeutics announces positive Phase 1 data at APASL 2024 for ALG-055009 and ALG-000184, showcasing strong antiviral activity and favorable safety profiles in liver diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
Rhea-AI Summary
Aligos Therapeutics initiates Phase 2a HERALD study for ALG-055009 in subjects with MASH, aiming to address unmet medical needs in liver diseases. Screening has commenced at clinical study sites with dosing of the first subject expected in Q2 2024 and topline data in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
-
Rhea-AI Summary
Aligos Therapeutics, Inc. (ALGS) reported significant progress in their drug development pipeline for liver and viral diseases in 2023. The company raised $92 million in a private placement financing, completed Phase 2a enabling activities for ALG-055009, and presented promising antiviral activity for chronic hepatitis B. Financially, Aligos ended 2023 with $135.7 million in cash, with net losses decreasing compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Aligos Therapeutics, Inc. (ALGS) will report its Q4 2023 financial results on March 12, 2024, focusing on liver and viral disease therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
Rhea-AI Summary
Aligos Therapeutics, Inc. (ALGS) will participate in one-on-one meetings at the Leerink Partners Global Biopharma Conference 2024 in Miami, Florida. The company focuses on developing therapeutics for liver and viral diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.33%
Tags
conferences
-
Rhea-AI Summary
Aligos Therapeutics to host a virtual KOL event featuring Dr. Stephen Harrison to discuss ALG-055009 and MASH therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
conferences clinical trial
-
Rhea-AI Summary
Aligos Therapeutics, Inc. (ALGS) appoints Jordyn Tarazi as VP of Investor Relations and Corporate Communications and Nikhil Aneja as VP of Finance. The company aims to enhance its team to support upcoming clinical data releases in liver and viral diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
management
Rhea-AI Summary
Aligos Therapeutics, Inc. (ALGS) presented clinical data for its CAM-E drug candidate, ALG-000184, and THR-β drug candidate, ALG-055009, at the Hep-DART 2023 meeting. ALG-000184 showed favorable safety and significant reductions in HBV markers, while ALG-055009 demonstrated favorable safety, lipid-lowering activity, and best-in-class potential for NASH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.77%
Tags
Aligos Therapeutics Inc

Nasdaq:ALGS

ALGS Rankings

ALGS Stock Data

63.18M
36.68M
21.07%
62.52%
1.15%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
South San Francisco

About ALGS

aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-㟠agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.